Group items tagged

The immune checkpoint inhibitors market was negatively impacted by the COVID-19 pandemic. Owing to decline in number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitors therapies which lead to decline in the demand of immune checkpoint inhibitors products. For instance, according to AstraZenca PLC, Opidivo (immune checkpoint inhibitor) registered a 5.6 % decline in

Here is a MIPS 2020 reporting checklist to ensure we are right on track and submit data right on time.